Development of an Animal Model for Mitochondrial Optic Neuropathy

Kamand Kavianpour1 , Fatemeh sadat Hosseini-Mazinani2 , Mahya Omrani, Zahra Amani3 , Dr.Leila Satarian - Dr.Farnoosh Khosrobakhsh4 *

  1. 1. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran 2. Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Iran.
  2. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  3. Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Iran.
  4. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran- Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Iran.

Abstract: Leber's hereditary optic neuropathy (LHON) is a mitochondrial and neurodegenerative disease that mainly affects retinal ganglion cells (RGCs).Complex 1 deficiency due to mitochondrial DNA mutation leads to visual failure. Rotenone, a mitochondrial complex I inhibitor, induced an increase in mitochondrial-derived free radicals and lipid peroxidation in primary mouse retinal cultures. The goal of current study was to develop an improved and highly reproducible rotenone model of LHON

Methods: In this study, male C57BL/6J (7-8 weeks old) were administered rotenone (2ul) in a specialized vehicle by intravitreal injection. Modeling is done only in one eye and the other eye is considered as a control. . After rotenone injection, vision test and morphometric test were performed at four time points (1h, 24h, 48h and 7days). Visual acuity was evaluated by optokinetic response (OKR). As mentioned above, LHON is characterized by decreasing retinal layers thickness and loss of RGCs, therefore the thickness of the retinal layers is measured by DAPI staining, and also RGCs viability is evaluated by immunohistochemistry technique. Finally, the results of different time points were compared.

Results: Surprisingly, the results obtained from morphometric tests was compromised by the visual tests. The thickness of retinal layers and the survival rate of retinal cells were significantly decreased 24 hours following intravitreal injection of rotenone as compared to control groups. Visual- and retinal- deficit induced by 48 hours and seven days after rotenone treatment was too severe. These results suggest that the mice received intravitreal administration of rotenone after 24 hours was considered the most suitable model of LHON.

Conclusion: Here, we established a mouse model of LHON by injecting rotenone in mice's eyes. Eyes exposed to rotenone displayed significantly loss of vision and alterations in retinal layers specially in inner plexiform layer. We demonstrated that rotenone induces retinal cell death by apoptosis resembling those observed in LHON patients. In summary, this version of the rotenone model is highly reproducible and may provide an excellent tool to test new neuroprotective strategies.





اخبــار



برگزار کنندگان کنگره


حامیان کنگره